Connection

Kwok-Yung Yuen to Drug Repositioning

Back to Details
This is a "connection" page, showing publications Kwok-Yung Yuen has written about Drug Repositioning.
Kwok-Yung Yuen
Connection Strength
0.398
Drug Repositioning
  1. Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. Nat Commun. 2021 03 09; 12(1):1517.
    View in: PubMed
    Score: 0.233
  2. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020 10; 586(7827):113-119.
    View in: PubMed
    Score: 0.056
  3. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. Pharmacol Res. 2020 09; 159:104960.
    View in: PubMed
    Score: 0.055
  4. Treatment With Lopinavir/Ritonavir or Interferon-ß1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis. 2015 Dec 15; 212(12):1904-13.
    View in: PubMed
    Score: 0.039
  5. Suppression of SARS-CoV-2 infection in ex-vivo human lung tissues by targeting class III phosphoinositide 3-kinase. J Med Virol. 2021 04; 93(4):2076-2083.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.